Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orion-BC: intravesical ONCOFID-P-B in BCG-unresponsive carcinoma in situ of the bladder
2024-512568-72-00Phase 3Authorised
- Sponsor
- Fidia Farmaceutici
- Start
- Feb 2023
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 6
01
Overview
Phase 3, open-label, single-arm trial of Oncofid-P-B in Bladder cancer in situ (CIS) and transitional cell carcinoma of the bladder (TCC), sponsored by Fidia Farmaceutici. Primary endpoint: Complete response rate at any time within 24 months. Planned start Feb 2023; status: authorised.
02
Drugs
Oncofid-P-B
03
Conditions
Bladder cancer in situ (CIS)transitional cell carcinoma of the bladder (TCC)
Beyond the preview
Go deeper on 2024-512568-72-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512568-72-00.